TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38290741
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patients receiving amiodarone treatment without cold application)
Study: 38290996
Drug: Interdisciplinary periodontal-orthodontic
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interdisciplinary periodontal-orthodontic treatment (mucogingival surgery using subepithelial connective tissue graft followed by orthodontic treatment)
Study: 38290996
Drug: Interdisciplinary periodontal-orthodontic
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interdisciplinary periodontal-orthodontic treatment
Study: 38291279
Drug: Bamlanivimab (BAM)
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bamlanivimab (BAM) 175 mg + Etesevimab (ETE) 350 mg
Study: 38291279
Drug: Bamlanivimab (BAM)
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bamlanivimab (BAM) 700 mg + Etesevimab (ETE) 1400 mg
Study: 38291279
Drug: Bamlanivimab (BAM)
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bamlanivimab (BAM) 2800 mg + Etesevimab (ETE) 2800 mg
Study: 38291279
Drug: Bamlanivimab (BAM)
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bamlanivimab (BAM) 700 mg alone
Study: 38291279
Drug: Bamlanivimab (BAM)
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bamlanivimab (BAM) 350 mg + Etesevimab (ETE) 700 mg
Study: 38291279
Drug: Bamlanivimab (BAM)
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bamlanivimab (BAM) 700 mg + Sotrovimab 500 mg
Study: 38291280
Drug: Kukoamine B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kukoamine B mesylate (KB) at doses of 0.005 mg/kg, 0.02 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.24 mg/kg, 0.48 mg/kg
Study: 38291372
Drug: Tovorafenib, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tovorafenib, administered once weekly at 420 mg/m2
Study: 38291372
Drug: Current standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current standard of care (SoC) chemotherapy
Study: 38291865
Drug: Lenvatinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib (12 mg for bodyweight ≥60 kg, 8 mg for bodyweight <60 kg) orally once daily, sintilimab (200 mg) intravenously once every 3 weeks, and on demand TACE
Study: 38291897
Drug: 0.6 million
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 million IU cholecalciferol oral
Study: 38293200
Drug: Pulsed low-dose-rate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed low-dose-rate radiation (PLDR) combined with chemotherapy
Study: 38293957
Drug: ABBV-599 (upadacitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-599 (upadacitinib 15 mg plus elsubrutinib 60 mg)
Study: 38293957
Drug: elsubrutinib 60
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: elsubrutinib 60 mg
Study: 38293957
Drug: elsubrutinib 20
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: elsubrutinib 20 mg
Study: 38293957
Drug: elsubrutinib 5
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: elsubrutinib 5 mg
Study: 38294016
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (50 Allergan units) in 1 mL of saline
Study: 38294016
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (1 mL)
Study: 38294091
Drug: LY3509754 (10-2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3509754 (10-2000 mg single ascending dose or 100-1000 mg multiple ascending dose for 14 days)
Study: 38294575
Drug: Experimental or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental or standard-of-care Enzyme Replacement Therapy (ERT)
Study: 39445704
Drug: NTLA-2002 25
Normalized name: NTLA-2002
DrugBank: NTLA-2002 (DB17597)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTLA-2002 25 mg
Study: 39445704
Drug: NTLA-2002 50
Normalized name: NTLA-2002
DrugBank: NTLA-2002 (DB17597)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTLA-2002 50 mg
Study: 38294975
Drug: NTLA-2002 75
Normalized name: NTLA-2002
DrugBank: NTLA-2002 (DB17597)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTLA-2002 75 mg
Study: 38294975
Drug: NTLA-2002 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTLA-2002 (all doses)
Study: 38295144
Drug: Paclitaxel (monotherapy)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (monotherapy)
Study: 38295144
Drug: Carboplatin (monotherapy)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (monotherapy)
Study: 38295317
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + Bevacizumab (CT + B)
Study: 38295954
Drug: Ficonalkib (SY-3505)
Normalized name: hydrogen peroxide
DrugBank: Ficonalkib (DB18774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ficonalkib (SY-3505) at 800 mg QD in phase 1
Study: 38295954
Drug: Ficonalkib (SY-3505)
Normalized name: hydrogen peroxide
DrugBank: Ficonalkib (DB18774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ficonalkib (SY-3505) at 600 mg QD in phase 2
Study: 38295954
Drug: Ficonalkib (SY-3505)
Normalized name: hydrogen peroxide
DrugBank: Ficonalkib (DB18774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ficonalkib (SY-3505) at 600 mg QD in phase 1/2
Study: 38296249
Drug: Shorter implants
Normalized name: SALICYLIC ACID 2 mg in 100 mL TOPICAL SHAMPOO [FYENACEL CALMING SHOOTER CELLANDIR HAIR LOSS-Shampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter implants (6 mm)
Study: 38296249
Drug: Standard-length implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-length implants (11-15 mm) with sinus grafting
Study: 38296273
Drug: Clinician-prescribed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-prescribed treatment without polyphenols
Study: 38296279
Drug: Focal ultra-hypofractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal ultra-hypofractionated salvage RT with 34 Gy in five fractions every other day and 6 months of androgen deprivation therapy
Study: 38296290
Drug: Oral ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ferric maltol
Study: 38296293
Drug: Clemastine fumarate
Normalized name: Clemastine Fumarate
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clemastine fumarate 4 mg two times a day for 6 months
Study: 38296588
Drug: Intravenous rhPro-UK
Normalized name: Vital E- Repro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rhPro-UK (35 mg)
Study: 38296849
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT pulmonary angiogram (CTPA) protocol
Study: 38297266
Drug: Caregiver-administered anthropometric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver-administered anthropometric assessments (no-contact protocol)
Study: 38297337
Drug: Vi-PS vaccine
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-PS vaccine (control)
Study: 38297399
Drug: FINGER 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: FINGER 2.0 intervention (lifestyle + metformin if eligible)
Study: 38297399
Drug: Metformin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2000 mg/day or 1000 mg/day)
Study: 38297524
Drug: Continue DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue DMARDs at 100% dose
Study: 38297524
Drug: Taper DMARDs
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper DMARDs to 50% dose
Study: 38297524
Drug: Stop DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop DMARDs after tapering to 50% dose for 6 months
Study: 38298125
Drug: mRNA-1345 (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1345 (50, 100, or 200 µg)
Study: 38298125
Drug: mRNA-1345 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1345 (100 µg)
Study: 38298125
Drug: mRNA-1345 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1345 (100 µg, 3 doses)
Study: 38298510
Drug: PSMA radioligand
Normalized name: Gallium-68 PSMA
DrugBank: Gallium-68 PSMA (DB16303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSMA radioligand therapy
Study: 38298551
Drug: Heart Rate
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart Rate Variability Biofeedback (HRV-B) intervention for 10 minutes twice daily for 4 weeks using Polar H10 ECG and Elite HRV app
Study: 38298861
Drug: Vedolizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab (300 mg) administered intravenously at weeks 0, 2, 6, then every 8 weeks for 26 or 52 weeks
Study: 38299059
Drug: ATI-1777 topical
Normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATI-1777 topical solution
Study: 38299416
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU cholecalciferol + placebo three times daily (Group I)
Study: 38299416
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg curcumin + 15,800 mg piperine once daily and three times daily placebo (Group II)
Study: 38299416
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU cholecalciferol three times daily and 600 mg curcumin + 15,800 mg piperine once daily (Group III)
Study: 38299667
Drug: Anti-CD74 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-CD74 therapy
Study: 38300292
Drug: Wild blueberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wild blueberry supplementation (single dose)
Study: 38300341
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus platinum-etoposide chemotherapy (200 mg pembrolizumab every 3 weeks, 75 mg cisplatin)
Study: 38300341
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus platinum-etoposide chemotherapy
Study: 38300408
Drug: Brodalumab 210
Normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 210 mg and Guselkumab 100 mg
Study: 38300838
Drug: Chamomile tea
Normalized name: Chamomile Tea
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile tea (3 g in 150 mL water)
Study: 38300838
Drug: Chamomile extract
Normalized name: Chamomile Extract
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile extract capsule (500 mg)
Study: 38302093
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral iron supplementation (dosage and duration not specified)
Study: 38302221
Drug: RVd/R (lenalidomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVd/R (lenalidomide 25 mg orally on days 1-14; bortezomib 1.3 mg/m2)
Study: 38302281
Drug: Tablet-based car
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based car restraint educational intervention using Computer Intervention Authoring Software (CIAS)
Study: 38302476
Drug: Guadecitabine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guadecitabine (starting at 60 mg/m²); duration not specified.
Study: 38302715
Drug: Sugemalimab (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugemalimab (1,200 mg) plus chemotherapy (cisplatin 80 mg)
Study: 38302715
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (cisplatin 80 mg)
Study: 38302725
Drug: Lenvatinib 20
Normalized name: LENVATINIB 20MG DAILY DOSE PACK,10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 20 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks (≤35 cycles)
Study: 38302725
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of physician's choice chemotherapy (TPC)
Study: 38302990
Drug: Habitual/Western dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habitual/Western dietary pattern (500 kcal/day from six non-MED target foods: cheesecake, chocolate frozen yogurt, refined grain bread, sour cream, white potato, and unprocessed, lean beef)
Study: 38304225
Drug: Phentermine 30
Normalized name: PHENTERMINE 30MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine 30 mg
Study: 38304225
Drug: PHEN/TPM (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHEN/TPM (15 mg/92 mg)
Study: 38304225
Drug: PHEN/TPM vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHEN/TPM vs Phentermine 30 mg
Study: 38305478
Drug: Intracanalicular dexamethasone
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracanalicular dexamethasone 0.4 mg
Study: 38305478
Drug: Topical prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prednisolone acetate (PA) 1%
Study: 38306883
Drug: 60 mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL/day EVOO
Study: 38307098
Drug: 927 mg
Normalized name: Sunlenca 927 MG 2-Vial Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 927 mg subcutaneous lenacapavir plus 30 mg/kg intravenous teropavimab and 10 mg/kg intravenous zinlirvimab
Study: 38307098
Drug: 927 mg
Normalized name: Sunlenca 927 MG 2-Vial Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 927 mg subcutaneous lenacapavir plus 30 mg/kg intravenous teropavimab and 30 mg/kg intravenous zinlirvimab
Study: 38307365
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (NA group)
Study: 38307365
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (non-NA group)
Study: 38307421
Drug: hsCRP ≥2
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsCRP ≥2 mg/L
Study: 38308203
Drug: T2DM patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T2DM patients after drug-induced mydriasis
Study: 38308227
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules containing n-3 LCPUFAs
Study: 38308248
Drug: Aquatic exercise
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic exercise intervention group (8-week, twice-weekly group-based Ai-Chi program)
Study: 38308655
Drug: Izuforant 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Izuforant 100 mg twice daily
Study: 38308746
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (IVR) combined with photodynamic therapy (PDT)
Study: 38308746
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (IVR) alone (monotherapy)
Study: 38309228
Drug: Low arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low arginine levels ≤90.05 μmol/l (n = 86; 37%)
Study: 38309282
Drug: Tabelecleucel administered
Normalized name: Tabelecleucel
DrugBank: Tabelecleucel (DB17072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabelecleucel administered intravenously at 2 × 10^6 cells/kg
Study: 38309287
Drug: Penpulimab plus
Normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penpulimab plus chemotherapy (paclitaxel 175 mg/m2 and carboplatin)
Study: 38309287
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (paclitaxel 175 mg/m2 and carboplatin)
Study: 38309492
Drug: H-VA-10 (vonoprazan
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-VA-10 (vonoprazan 20 mg b.i.d. + amoxicillin 750 mg 4 times a day, 10 days)
Study: 38309492
Drug: H-VA-14 (vonoprazan
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-VA-14 (vonoprazan 20 mg b.i.d. + amoxicillin 750 mg 4 times a day, 14 days)
Study: 38309492
Drug: L-VA-10 (vonoprazan
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-VA-10 (vonoprazan 20 mg b.i.d. + amoxicillin 1000 mg b.i.d, 10 days)
Study: 38309519
Drug: Oral valganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valganciclovir for 6 weeks
Study: 38309721
Drug: TIL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIL therapy with lymphodepleting chemotherapy followed by infusion of ex vivo expanded TIL manufactured with IL-2 and agonistic stimulation of CD3 and 4-1BB (urelumab); patients received up to six doses of high-dose IL-2 after TIL infusion.
Study: 38309722
Drug: Monalizumab 750
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monalizumab 750 mg Q2W plus durvalumab 1500 mg Q4W (cervical cancer; n=15)
Study: 38309722
Drug: Monalizumab 750
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monalizumab 750 mg Q2W plus durvalumab 1500 mg Q4W (MSS-CRC; n=15)
Study: 38309722
Drug: Monalizumab 750
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monalizumab 750 mg Q2W plus durvalumab 1500 mg Q4W (NSCLC; n=20)
Study: 38309722
Drug: Monalizumab 750
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monalizumab 750 mg Q2W plus durvalumab 1500 mg Q4W (ovarian cancer; n=40)
Study: 38309722
Drug: Monalizumab 750
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monalizumab 750 mg Q2W plus durvalumab 1500 mg Q4W (MSS-endometrial cancer; n=40)
Study: 38309733
Drug: Cuffed endotracheal
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cuffed endotracheal tubes (ETTs) of size 4.5; mean ideal cuff volume inflated was 1.7±0.3 ml
Study: 38309733
Drug: Cuffed endotracheal
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cuffed endotracheal tubes (ETTs) of size 5.0; mean ideal cuff volume inflated was 1.9±0.3 ml
Study: 38309733
Drug: Cuffed endotracheal
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cuffed endotracheal tubes (ETTs) of size 5.5; mean ideal cuff volume inflated was 2.1±0.3 ml
Study: 38309733
Drug: Formula developed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula developed for predicting cuff volume: endotracheal cuff volume (ml) = 1.027 x height (m) + 0.104 x subglottic transverse diameter (mm) - 0.0191
Study: 38309748
Drug: SCRT followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SCRT followed by four cycles of CAPOX and PD-1 inhibitor (serplulimab)
Study: 38309761
Drug: ETT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETT with subglottic secretion drainage (Taper Guard, Covidien)
Study: 38309829
Drug: Small-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-quantity lipid-based nutrient supplements (SQ-LNS) during pregnancy and 6 months postpartum
Study: 38310035
Drug: Domvanalimab 1200
Normalized name: Domvanalimab
DrugBank: Domvanalimab (DB18848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domvanalimab 1200 mg plus zimberelimab 360 mg plus platinum-doublet chemotherapy (PT)
Study: 38310035
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg plus PT
Study: 38310035
Drug: Zimberelimab 360
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimberelimab 360 mg plus PT
Study: 38310192
Drug: KN046 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: KN046 (3 mg/kg or 5 mg/kg) combined with nab-paclitaxel
Study: 38310261
Drug: guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 100 mg at week 0, week 4, then every 8 weeks
Study: 38310286
Drug: Irinotecan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (50 mg/m²) and Anlotinib
Study: 38310910
Drug: R21/Matrix-M vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: R21/Matrix-M vaccine
Study: 38310910
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (licensed rabies vaccine [Abhayrab])
Study: 38310920
Drug: NNC0385-0434 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0385-0434 15 mg
Study: 38310920
Drug: NNC0385-0434 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0385-0434 40 mg
Study: 38310920
Drug: NNC0385-0434 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0385-0434 100 mg
Study: 38310920
Drug: Evolocumab 140
Normalized name: evolocumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 140 mg
Study: 38312318
Drug: High-dose-rate brachytherapy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate brachytherapy (HDRBT)
Study: 38312318
Drug: Low-dose-rate brachytherapy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose-rate brachytherapy (LDRBT)
Study: 38314010
Drug: TheraTogs +
Approvals — FDA: no, EMA: no, PMDA: no
Description: TheraTogs + Conventional Physical Therapy (CPT)
Study: 38314643
Drug: Buspirone/Zolmitriptan (10/1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone/Zolmitriptan (10/1.25 mg three times a day)
Study: 38315466
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel
Study: 38315777
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (specific type not mentioned)
Study: 38315832
Drug: 3L cellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3L cellular immunotherapy after SOC (n=68)
Study: 38315832
Drug: 3L therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3L therapy not receiving cellular immunotherapy after SOC (n=59)
Study: 38315832
Drug: 3L chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3L chemotherapy after axi-cel (n=60)
Study: 38315832
Drug: 3L cellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3L cellular immunotherapy after axi-cel (n=8)